Best of Angiogenesis, Exudation, and Degeneration 2024 – Virtual Edition

Topic outline

• 

  Description

  Angiogenesis, Exudation, and Degeneration 2024 featured an exceptional group of basic scientists, clinicians, and healthcare experts, all focused on understanding and treating neovascular, exudative, and degenerative diseases of the eye. The program highlighted the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, retinopathy of prematurity, and inherited retinal degenerations with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare. To see the full program agenda, please click here.
  

  Presentation Date: 02/03/2024
  

  • Course Directors
    

  • Philip J. Rosenfeld, MD, PhD URL
  • Harry W. Flynn, Jr., MD URL
  • Thomas A. Albini, MD URL
  • Videos
    

  • Ophthalmic Artery Angioplasty for GA: Rationale, Perspectives, and Early Outcomes by Mario J. Saravia, MD, PhD URL
  • LIGHTSITE III 24-Month Analysis: Evaluation of Multiwavelength Photobiomodulation in Dry Age-Related Macular Degeneration by Eleonora M. Lad, MD, PhD URL
  • First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD by Arshad M. Khanani, MD, MA URL
  • THE DAVIO 2 TRIAL: Topline Data from a Phase 2, Multicenter Study of a Single Injection of EYP-1901 (Vorolanib in the Durasert E™ Technology) vs Aflibercept for Previously Treated Wet Age-Related Macular Degeneration by Charles C. Wykoff, MD, PhD URL
  • 96-week Efficacy and Safety of Aflibercept 8 mg in nAMD: An Update from the PULSAR Study by W. Lloyd Clark, MD URL
  • Faricimab in RVO: 72-Week Results From the BALATON and COMINO Phase 3 Studies by Ramin Tadayoni, MD, PhD URL